Teva and modag announce licensing collaboration for neurodegenerative disease drug candidate

Tel aviv & wendelsheim, germany--(business wire)--teva pharmaceutical industries ltd. (nyse and tase: teva) and modag gmbh today announced a strategic collaboration on the exclusive worldwide licensing and development of modag's lead compound anle138b and a related compound, sery433. anle138b targets pathological alpha-synuclein oligomers and is being evaluated in patients with neurodegenerative diseases for potential disease modification. under the terms of the agreement and pending regulatory
TEVA Ratings Summary
TEVA Quant Ranking